impact:

Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies

According to PR-model, Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies is ranked 1,526,555^th in multilingual Wikipedia, in particular this website is ranked 1,215,300^th in English Wikipedia.

#Language

PR-model F-model AR-model

*All Wikipedias

1,526,555^th place

1,427,977^th place

1,610,452^nd place

enEnglish

1,215,300^th place

827,334^th place

1,273,313^th place